S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Public Service Announcement: New National Emergency Incoming (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Better Than Oil Stocks (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Better Than Oil Stocks (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Public Service Announcement: New National Emergency Incoming (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Better Than Oil Stocks (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Better Than Oil Stocks (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Public Service Announcement: New National Emergency Incoming (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Better Than Oil Stocks (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Better Than Oil Stocks (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Public Service Announcement: New National Emergency Incoming (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Better Than Oil Stocks (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Better Than Oil Stocks (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
NASDAQ:NKTR

Nektar Therapeutics (NKTR) Stock Price, News & Analysis

$0.68
+0.02 (+3.02%)
(As of 02/23/2024 ET)
Today's Range
$0.63
$0.70
50-Day Range
$0.47
$0.77
52-Week Range
$0.41
$1.82
Volume
1.07 million shs
Average Volume
1.08 million shs
Market Capitalization
$130.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Nektar Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.86 Rating Score
Upside/​Downside
339.6% Upside
$3.00 Price Target
Short Interest
Bearish
3.04% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.77
Upright™ Environmental Score
News Sentiment
0.11mentions of Nektar Therapeutics in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$19,752 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.83) to ($0.87) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.79 out of 5 stars

Medical Sector

237th out of 941 stocks

Pharmaceutical Preparations Industry

106th out of 432 stocks


NKTR stock logo

About Nektar Therapeutics Stock (NASDAQ:NKTR)

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

NKTR Stock Price History

NKTR Stock News Headlines

The Retirement of Your Dreams Awaits You…
Imagine it's 2025 and you have the financial freedom to pursue any of your biggest goals. All of this because YOU decided to take action in 2024. The Bitcoin Halving in 2024 could change your life forever...And the strategies outlined in the Crypto Retirement Blueprint will give you what you need to be able to crush the upcoming halving cycle bull run, and potentially retire quickly in wealth.
DiaMedica Appoints Lorianne Masuoka As Chief Medical Officer
The Retirement of Your Dreams Awaits You…
Imagine it's 2025 and you have the financial freedom to pursue any of your biggest goals. All of this because YOU decided to take action in 2024. The Bitcoin Halving in 2024 could change your life forever...And the strategies outlined in the Crypto Retirement Blueprint will give you what you need to be able to crush the upcoming halving cycle bull run, and potentially retire quickly in wealth.
Positive Report for Nektar Therapeutics (NKTR) from TD Cowen
Recap: Nektar Therapeutics Q3 Earnings
Nektar Therapeutics Q3 Loss decreases, but misses estimates
A Preview Of Nektar Therapeutics's Earnings
See More Headlines
Receive NKTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/08/2023
Today
2/23/2024
Next Earnings (Estimated)
2/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:NKTR
CUSIP
64026810
Employees
216
Year Founded
1990

Price Target and Rating

Average Stock Price Target
$3.00
High Stock Price Target
$6.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+339.6%
Consensus Rating
Reduce
Rating Score (0-4)
1.86
Research Coverage
7 Analysts

Profitability

Net Income
$-368,200,000.00
Net Margins
-332.73%
Pretax Margin
-329.36%

Debt

Sales & Book Value

Annual Sales
$92.06 million
Book Value
$1.95 per share

Miscellaneous

Free Float
184,914,000
Market Cap
$130.18 million
Optionable
Optionable
Beta
0.78

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Howard W. RobinMr. Howard W. Robin (Age 71)
    CEO, President & Director
    Comp: $1.83M
  • Mr. Mark A. Wilson (Age 52)
    Senior VP, Chief Legal Officer & Secretary
    Comp: $749.99k
  • Dr. Jonathan Zalevsky Ph.D. (Age 49)
    Senior VP & Chief Research and Development Officer
    Comp: $1.25M
  • Ms. Sandra A. Gardiner (Age 58)
    Chief Financial Officer
  • Vivian Wu
    Director of Investor Relations & Corporate Affairs
  • Mr. Robert Bacci
    Senior Vice President of Human Resources & Facilities Operations
  • Ms. Jennifer Ruddock
    Chief Business Officer
  • Dr. Mary Tagliaferri L.Ac. (Age 58)
    M.D., Chief Medical Officer
  • Dr. Loui T. Madakamutil
    VP and Head of Discovery & Research














NKTR Stock Analysis - Frequently Asked Questions

Should I buy or sell Nektar Therapeutics stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 2 sell ratings, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" NKTR shares.
View NKTR analyst ratings
or view top-rated stocks.

What is Nektar Therapeutics' stock price target for 2024?

6 brokerages have issued twelve-month price targets for Nektar Therapeutics' shares. Their NKTR share price targets range from $1.00 to $6.00. On average, they expect the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 339.6% from the stock's current price.
View analysts price targets for NKTR
or view top-rated stocks among Wall Street analysts.

How have NKTR shares performed in 2024?

Nektar Therapeutics' stock was trading at $0.5650 at the beginning of the year. Since then, NKTR shares have increased by 20.8% and is now trading at $0.6824.
View the best growth stocks for 2024 here
.

Are investors shorting Nektar Therapeutics?

Nektar Therapeutics saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 5,800,000 shares, an increase of 6.6% from the January 15th total of 5,440,000 shares. Based on an average daily volume of 1,210,000 shares, the days-to-cover ratio is presently 4.8 days.
View Nektar Therapeutics' Short Interest
.

When is Nektar Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our NKTR earnings forecast
.

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) issued its quarterly earnings data on Tuesday, August, 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.03. The biopharmaceutical company had revenue of $20.50 million for the quarter, compared to analysts' expectations of $20.94 million. Nektar Therapeutics had a negative trailing twelve-month return on equity of 80.44% and a negative net margin of 332.73%. During the same period in the prior year, the business posted ($0.85) EPS.

What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO?

46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Nektar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY).

Who are Nektar Therapeutics' major shareholders?

Nektar Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (6.31%), Primecap Management Co. CA (3.67%), Monaco Asset Management SAM (3.13%), GSA Capital Partners LLP (2.76%), Assenagon Asset Management S.A. (1.29%) and Balyasny Asset Management L.P. (0.58%). Insiders that own company stock include Gil M Labrucherie, Gil M Labrucherie, Howard W Robin, Howard W Robin, Jillian B Thomsen, Jillian B Thomsen, John Northcott, Jonathan Zalevsky, Karin Eastham, Mark Andrew Wilson, Myriam Curet, Robert Chess and Roy A Whitfield.
View institutional ownership trends
.

How do I buy shares of Nektar Therapeutics?

Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NKTR) was last updated on 2/24/2024 by MarketBeat.com Staff